Fruquintinib in combination with pd-1 inhibitors in patients with refractory non-msi-h/pmmr metastatic colorectal cancer: a real-world study in china

HIGHLIGHTS

• who: Miaomiao Gou from the A Real-World Study in China Shanghai Jiao Tong University, China have published the research work: Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China, in the Journal: (JOURNAL)
• what: The reason for the discrepancies between studies might lie in the fact that the REGONIVO study was a dose-finding and dose-expansion phase 1b trial, which was aimed to exploring the safety and recommended doses. Considering real-world studies do not limit PS scores . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.